New Research Points to BCL6 as a Potential Target to Stop Type 1 Diabetes Development

Researchers studying type 1 diabetes have identified a new target that could lead to more precise treatments. The focus is on a protein called BCL6, which plays a role in organizing immune responses. In laboratory studies, removing BCL6 from a specific type of T cell prevented diabetes from developing, even though the anti-insulin B cells that typically trigger the disease were still present.

Type 1 diabetes develops when the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. This attack is orchestrated by multiple immune cells working together. The new research reveals that T cells rely on BCL6 to activate and support the B cells that recognize insulin as a threat. When BCL6 was removed from T cells, these anti-insulin B cells were less active and less able to proliferate. The B cells that did remain tended to be found in areas outside the typical immune structures and showed signs of being less problematic.

This finding suggests that BCL6 acts as a critical link between T cells and the B cells that drive the autoimmune attack. By interrupting this connection, researchers may be able to prevent diabetes without broadly suppressing the entire immune system.

Current approved therapies for type 1 diabetes work by dampening T cell activity broadly. While these treatments can delay the onset of diabetes, they do not fully prevent it and can weaken immune responses to infection and other threats. The BCL6 approach studied here was more selective—it specifically blocked the interaction between T cells and anti-insulin B cells without shutting down all immune function. This precision could potentially offer better protection with fewer side effects, though this remains to be tested in people.

This research was conducted in laboratory models and represents an early stage of discovery. The findings support the idea that BCL6 inhibition is worth investigating further as a potential immunotherapy for type 1 diabetes. Before any treatment could reach patients, researchers would need to develop drugs that can safely inhibit BCL6 in the right way, and then test them in clinical trials. The work offers a promising new direction for scientists seeking more targeted approaches to prevent type 1 diabetes.

Source: iScience. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.